Key Highlights

  • Ping An Biomedical Co., Ltd. (NASDAQ:PASW) traded at USD 1.70, down 41.98% in trading on November 5, 2026, per published market data, on Volume of about 67,000 shares.
  • On November 4, 2026 the company announced a definitive agreement to buy three tumor cell patents from Future Biotechnology Group Co., Limited for USD 2.3 million.
  • The deal follows a non-binding letter of intent dated October 22, 2026, and closing and registration steps are still pending.
  • A 1-for-40 Reverse Stock Split was announced on October 21, 2026, per published coverage, and one Shareholder holds about 91.56% of voting power.

A Patent Purchase Marks a Move Into Biomedicine

Ping An Biomedical Co., Ltd. (NASDAQ:PASW) announced on November 4, 2026 that it signed a definitive agreement to acquire three tumor cell related medical technology patents from Future Biotechnology Group Co., Limited for USD 2.3 million. The patents cover oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies. The agreement followed a non-binding letter of intent dated October 22, 2026. The announcement did not state the form of payment, and closing and registration steps remain pending. A separate proposed strategic Investment in the seller is still under negotiation.

An Apparel Supply Chain Business Changing Direction

The company is a Cayman Islands Holding Company whose operations run through a Chinese Subsidiary providing supply chain management services for the apparel industry, covering yarn products, textiles and finished garments. Buying oncology patents is therefore a sharp change of direction, and patents alone do not generate Revenue until they are developed, licensed or commercialized. In a shelf registration the company set out plans to offer up to USD 300 million of securities, and in February 2026 it agreed to sell 100 million ordinary shares at USD 0.04 each for USD 4 million. A reverse split of 1-for-40, announced October 21, 2026, consolidates every 40 shares into one and raises the quoted price without changing company value.

Risks: Thin Trading, Control and Dilution

With a Market Value of roughly USD 5 million per published market data, a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so the drop should not be read as a trend. About 91.56% of voting power sits with one shareholder, limiting the influence of outside holders. A shelf of that size relative to the company raises dilution risk, and reverse splits often precede further share issuance. The price also remains tied to Nasdaq minimum bid price compliance. Watch for the closing of the patent purchase, payment terms and the outcome of the Future Biotechnology Group investment talks.

Where Things Stand

Ping An Biomedical Co., Ltd. (NASDAQ:PASW) fell because a tiny, thinly traded stock is repricing a strategic pivot whose Economics are not yet clear. The USD 2.3 million patent purchase has no disclosed payment form, closing is pending, and the legacy apparel business gives little guidance on how the patents will earn revenue. Concentrated voting control and a large shelf add dilution risk, while the quoted move is intraday and can reverse. The next markers are the closing of the patent deal and any decision on the strategic investment.